Avanos Medical Inc

Avanos Medical, Inc. operates as a medical technology company. It focuses on delivering clinically medical device solutions to improve patients' quality of life. The firm’s portfolio of product offerings focuses on respiratory and digestive health, along with surgical and interventional pain management to improve patient outcomes and reduce the cost of care. Its brands include ON-Q, Coolife, Microcuff, MIC-Key, Quilbloc and Home pump. The company was founded on February 25, 2014 and is headquartered in Alpharetta, GA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Avanos Medical Inc reports robust Q4 results and outlines growth strategies

Avanos Medical Inc delivered strong financial performance in Q4 2022, showcasing growth in key product categories and exceeding expectations in OrthogenRx. While facing challenges in certain segments, Avanos is focused on optimizing operations and capitalizing on identified opportunities for growth.

Avanos Medical reports steady Q1 performance amidst strategic transformation

Avanos Medical Inc's Q1 2023 performance was steady, with a focus on operational efficiency and profitability enhancement.
While facing challenges in certain product categories, Avanos is well-positioned to capitalize on growth opportunities through strategic initiatives.
The company's transformation priorities and guidance for the year reflect a proactive approach to navigating market dynamics and driving sustainable value creation.

Avanos Medical Inc reports resilient Q2 performance and outlines growth strategies

Avanos Medical Inc demonstrated resilience in Q2 amidst supply chain challenges and inflation effects.
The company's focus on strategic priorities and shareholder value enhancement initiatives bode well for future growth.
Despite some portfolio challenges, Avanos remains optimistic about mid-single-digit revenue growth in 2024.
Operational efficiency and growth opportunities in key product lines position Avanos for sustained success.

Avanos Medical Inc reports Q3 results, focuses on efficiency and growth

Avanos Medical Inc's Q3 performance reflects mixed results with growth in Digestive Health but decline in Pain Management portfolios.
The company's transformation priorities and cost management efforts aim to drive efficiency and optimize performance.
Despite challenges in certain product segments, Avanos Medical Inc's focus on gross margin improvement and savings targets bode well for future profitability.
Opportunities lie in portfolio transformation, enhanced gross margins, and strategic initiatives like DIros Technology and cost optimization.

Avanos Medical Inc reports stable Q4 earnings amidst growth strategies

Avanos Medical Inc's Q4 performance reflects mixed results with challenges in certain product segments but stable profitability.
The company's strategic priorities aim to drive future growth through portfolio optimization and cost management.
Anticipated revenue growth, focus on M&A, and long-term financial targets position Avanos for sustainable performance and expansion.

Avanos Medical Inc reports solid Q1 performance and growth outlook

Avanos Medical Inc's Q1 2024 performance showed mixed results across portfolios but strong overall financials.
The company's focus on cost management, capital efficiency, and strategic targets bodes well for future growth.
Despite challenges in certain product lines, Avanos remains confident in its strategies and growth trajectory.

Avanos Medical reports resilient Q2 results amidst portfolio growth

Avanos Medical's Q2 performance showcased solid sales figures and growth in key portfolios, despite challenges in certain segments.
The company's strengths lie in maintaining financial guidance, a strong balance sheet, and a strategic focus on transformation initiatives.
While facing challenges in specific product lines, Avanos Medical has opportunities to drive growth through product innovation, strategic partnerships, and capital allocation.
Overall, Avanos Medical remains committed to its transformation journey and delivering value to shareholders through prudent financial management.

Avanos Medical reports Q3 results, focuses on growth strategies

Avanos Medical's Q3 performance reflects a mixed picture with strong Digestive Health growth but challenges in the pain portfolio.
The company's strategic focus on high-margin products, cost management, and growth initiatives positions it for future success.
Despite current challenges, Avanos Medical's pursuit of organic growth, efficient capital allocation, and strategic M&A bode well for long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Avanos Medical, Inc. is a medical technology company, which engages in delivering clinically superior medical device solutions and products to healthcare providers and patients. The company was founded on February 25, 2014 and is headquartered in Alpharetta, GA.

Avanos Medical (AVNS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Avanos Medical (AVNS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

ALPHARETTA, Ga. , Oct. 25, 2023 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the third quarter 2023 on Wednesday, Nov. 1 at 9 a.m.

Avanos Medical, Inc. to Webcast Conference Call Discussing Third Quarter 2023 Financial Results

GRAND RAPIDS, Mich.--(BUSINESS WIRE)--AirLife, a leading North American manufacturer and distributor of consumable medical devices for anesthesia and respiratory care formerly known as SunMed, today announced the completion of its acquisition of Avanos Medical, Inc.'s (NYSE: AVNS) (“Avanos”) respiratory health business, including the BALLARD*, MICROCUFF* and endOclear® product lines. The acquisition adds three complementary brands, the R&D expertise behind them and two manufacturing facilit.

AirLife Completes Acquisition of Avanos Medical's Respiratory Health Business

ALPHARETTA, Ga. , Sept. 12, 2023 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Michael Greiner, senior vice president, chief financial officer, and chief transformation officer will participate in a fireside chat at CL King's virtual 21st Annual Best Ideas Conference 2023 on Mon.

Avanos Medical, Inc. to Present at the CL King Annual Best Ideas Conference

Despite strength in Avanos' (AVNS) Digestive Health segment, its overall second-quarter results reflect soft performances.

Avanos (AVNS) Q2 Earnings and Revenues Fall Shy of Estimates

Avanos Medical Inc. (NYSE:AVNS ) Q2 2023 Results Conference Call August 9, 2023 9:00 AM ET Company Participants Joe Woody - CEO and Director Scott Galovan - Vice President of Strategy and Corporate Development Michael Greiner - Senior VP, CFO and Chief Transformation Officer Conference Call Participants Rick Wise - Stifel Matthew Mishan - KeyBanc Kristen Stewart - CL King Daniel Stauder - JMP Securities Operator Good morning, everyone, and welcome to the Avanos Second Quarter 2023 Earnings Conference Call. All participants are in a listen-only mode.

Avanos Medical Inc. (AVNS) Q2 2023 Earnings Call Transcript

Avanos Medical (AVNS) came out with quarterly earnings of $0.24 per share, missing the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.41 per share a year ago.

Avanos Medical (AVNS) Q2 Earnings and Revenues Lag Estimates

ALPHARETTA, Ga. , Aug. 9, 2023 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported second quarter 2023 financial results.

Avanos Medical, Inc. Announces Second Quarter 2023 Results

ALPHARETTA, Ga. , Aug. 8, 2023 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Michael Greiner, senior vice president, chief financial officer, and chief transformation officer will participate in a fireside chat at the UBS MedTech, Tools and Genomics Summit 2023 on Tues.

Avanos Medical, Inc. to Present at the UBS MedTech, Tools and Genomics Summit 2023

ALPHARETTA, Ga. , Aug. 2, 2023 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the second quarter 2023 on Wednesday, Aug. 9 at 9 a.m.

Avanos Medical, Inc. to Webcast Conference Call Discussing Second Quarter 2023 Financial Results

Edwards Lifesciences

Investors interested in stocks from the Medical - Instruments sector have probably already heard of Avanos Medical (AVNS) and Edwards Lifesciences (EW). But which of these two stocks offers value investors a better bang for their buck right now?

AVNS vs. EW: Which Stock Is the Better Value Option?

Avanos Medical, Inc. (AVNS) continues its focus on a leaner cost structure and repurposing of capital. The struggling respiratory health business has been sold off, with the transaction due to settle in Q4 this year. Despite financial headwinds, AVNS is increasing capital productivity and my number project $802.8mm and $833mm in sales in FY'23 and FY'24, respectively.

Avanos Medical: Leaning Up, Attractive Returns On Incremental Capital, Reiterate Buy

New guidance supports use of radiofrequency ablation for osteoarthritic knee pain ALPHARETTA, Ga. , June 28, 2023 /PRNewswire/ -- Avanos Medical supports the announcement today from the UK's National Institute for Health and Care Excellence (NICE) recommending the use of radiofrequency ablation (RFA) for the treatment of osteoarthritic knee pain.

Avanos Medical Supports New Interventional Procedure Recommendations from the UK's National Institute of Health and Care Excellence (NICE)

Avanos' (AVNS) latest acquisition is expected to strengthen its foothold with a comprehensive suite of RF offerings.

Avanos' (AVNS) Latest Buyout to Boost Its RF Product Offering

Unique tined-probe technology further differentiates Avanos portfolio ALPHARETTA, Ga. , June 19, 2023 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced it has entered into a definitive agreement to acquire Diros Technology Inc., a leading manufacturer of innovative radiofrequency (RF) products used to treat chronic pain conditions.

Avanos Medical, Inc. Announces Agreement to Acquire Diros Technology Inc.

ALPHARETTA, Ga. , June 13, 2023 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that it will host an Investor Day at Convene on 101 Park Avenue, New York, on Tuesday, June 20th, 2023.

Avanos Medical, Inc. To Host Investor Day on June 20, 2023

GRAND RAPIDS, Mich.--(BUSINESS WIRE)--SunMed, a leading North American manufacturer and distributor of consumable medical devices for anesthesia and respiratory care, today announced it has entered into a definitive agreement with Avanos Medical, Inc. (NYSE: AVNS) (“Avanos”), under which SunMed will acquire Avanos' respiratory health business, including the BALLARD*, MICROCUFF* and endOclear® product lines. This combination further expands the breadth of SunMed's leading product offering, provi.

SunMed to Acquire Avanos Medical's Respiratory Health Business

ALPHARETTA, Ga. , June 8, 2023 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced it has entered into a definitive agreement to sell its Respiratory Health (RH) business to SunMed Group Holdings, LLC (SunMed).

Avanos Medical, Inc. Announces Sale of Respiratory Health Business to SunMed Group Holdings, LLC

Despite strength in Avanos' (AVNS) Chronic Care segment, its overall first-quarter results reflect soft performances.

Avanos (AVNS) Q1 Earnings and Revenues Fall Shy of Estimates

Avanos Medical, Inc. (NYSE:AVNS ) Q1 2023 Earnings Conference Call May 3, 2023 9:00 AM ET Company Participants Scott Galovan - SVP, Strategy and M&A Joe Woody - CEO Michael Greiner - SVP, CFO, and Chief Transformation Officer Conference Call Participants Rick Wise - Stifel Matthew Mishan - KeyBanc Drew Ranieri - Morgan Stanley Operator Good morning and welcome to the Avanos Q1 Earnings Conference Call. All participants will be in listen-only mode.

Avanos Medical, Inc. (AVNS) Q1 2023 Earnings Call Transcript

Avanos Medical (AVNS) came out with quarterly earnings of $0.27 per share, missing the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.26 per share a year ago.

Avanos Medical (AVNS) Q1 Earnings and Revenues Lag Estimates

ALPHARETTA, Ga. , May 3, 2023 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported first quarter 2023 financial results.

Avanos Medical, Inc. Announces First Quarter 2023 Results

ALPHARETTA, Ga. , April 26, 2023 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the first quarter 2023 on Wednesday, May 3 at 9 a.m.

Avanos Medical, Inc. to Webcast Conference Call Discussing First Quarter 2023 Financial Results

Avanos Medical: Cost Restructuring Could Unlock Substantial Value.

Avanos Medical: Cost Restructuring Could Unlock Substantial Value

Here is how Avanos Medical (AVNS) and Becton Dickinson (BDX) have performed compared to their sector so far this year.

News for Avanos Medical Inc Stock (AVNS)